AbbVie(US:ABBV) Prnewswire·2025-11-12 13:30Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, is showcasing its leadership in the aesthetic industry by presenting 17 abstracts at the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, including three in the "Top Ten" session [1][2] - The presentations will cover Phase 3 clinical study results for trenibotulinumtoxinE, a first-in-class botulinum neurotoxin, and a Phase 4 study on BOTOX® Cosmetic, focusing on patient satisfaction and natural outcomes [1][3] - The company emphasizes its commitment to evidence-based innovation and improving patient care through its diverse product portfolio [2] Presentation Highlights - Key presentations include the efficacy and safety of trenibotulinumtoxinE for treating glabellar lines, and patient-reported satisfaction following BOTOX® Cosmetic treatment for upper facial lines [4][5] - An expert panel will discuss insights from the "Hyaluronic Acid Injectable Fillers Report," focusing on current usage and satisfaction data for hyaluronic acid fillers [4] - A symposium will address the latest indications for BOTOX® Cosmetic, including treatment for moderate to severe platysma bands [4] Educational Initiatives - Allergan Aesthetics will host educational programs aimed at understanding patient needs and enhancing clinical practices [3] - Presentations will also cover the benefits of long-term BOTOX® Cosmetic use and survey results on aesthetic concerns following medical weight loss [3][4] Company Overview - Allergan Aesthetics develops and markets a wide range of aesthetic products, including facial injectables and body contouring solutions, with a focus on innovation and customer service [30] - AbbVie aims to address serious health issues through innovative medicines, with a significant presence in the aesthetics market [31]